Rett Syndrome: A Prototypical Neurodevelopmental Disorder

Neuroscientist

Volumn 10, Issue 2, 2004, Pages 118-128

  Neul, Jeffrey L ^a   Zoghbi, Huda Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angelman; Autism; MBD; MeCP2; Synapse

Indexed keywords

DNA; METHYL CPG BINDING PROTEIN 2;

ANIMAL MODEL; AUTISM; CHROMATIN STRUCTURE; DEVELOPMENTAL DISORDER; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENOTYPE; HAPPY PUPPET SYNDROME; HUMAN; MENTAL DEFICIENCY; MOUSE; NONHUMAN; OLFACTORY SYSTEM; PHENOTYPE; PRIORITY JOURNAL; RETT SYNDROME; REVIEW;

ANIMALS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CHROMOSOMAL PROTEINS, NON-HISTONE; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; MALE; MENTAL RETARDATION; METHYL-CPG-BINDING PROTEIN 2; MODELS, MOLECULAR; MUTATION; PHENOTYPE; REPRESSOR PROTEINS; RETT SYNDROME; SYNAPSES;

EID: 1642367538     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073858403260995     Document Type: Review

References (104)

1. Akbarian S, Chen RZ, Gribnau J, Rasmussen TP, Fong H, Jaenisch R, and others. 2001. Expression pattern of the Rett syndrome gene MeCP2 in primate prefrontal cortex. Neurobiol Dis 8(5):784-91.
2. Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, and others. 2000. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 47(5):670-9.
3. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23(2):185-8.
4. Armstrong D, Dunn JK, Antalffy B, Trivedi R. 1995. Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol 54(2):195-201.
5. Armstrong DD. 2002. Neuropathology of Rett syndrome. Ment Retard Dev Disabil Res Rev 8(2):72-6.
6. Armstrong DD, Dunn JK, Schultz RJ, Herbert DA, Glaze DG, Motil KJ. 1999. Organ growth in Rett syndrome: a postmortem examination analysis. Pediatr Neurol 20(2):125-9.
7. Armstrong J, Pineda M, Aibar E, Gean E, Monros E. 2001. Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation. Ann Neurol 50(5):692.
8. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, and others. 1995. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25(1):63-77.
9. Balmer D, Goldstine J, Rao YM, LaSalle JM. 2003. Elevated methyl-CpG-binding protein 2 expression is acquired during postnatal human brain development and is correlated with alternative polyadenylation. J Mol Med 81(1):61-8.
10. Belichenko PV, Oldfors A, Hagberg B, Dahlstrom A. 1994. Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport 5(12):1509-13.
11. Beyer KS, Blasi F, Bacchelli E, Klauck SM, Maestrini E, Poustka A. 2002. International Molecular Genetic Study of Autism C. Mutation analysis of the coding sequence of the MECP2 gene in infantile autism. Hum Genet 111(4-5):305-9.
12. Bienvenu T, Carrie A, de Roux N, Vinet MC, Jonveaux P, Couvert P, and others. 2000. MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum Mol Genet 9(9):1377-84.
13. Butz S, Okamoto M, Sudhof TC. 1998. A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. Cell 94(6):773-82.
14. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro ML, and others. 2003. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr Neurol 28(3):205-11.
15. Chae JH, Hwang YS, Kim KJ. 2002. Mutation analysis of MECP2 and clinical characterization in Korean patients with Rett syndrome. J Child Neurol 17(1):3-36.
16. Chandler SP, Guschin D, Landsberger N, Wolffe AP. 1999. The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA. Biochemistry 38(22):7008-18.
17. Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, Leonard H, and others. 2000. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet 9(7):1119-29.
18. Chen RZ, Akbarian S, Tudor M, Jaenisch R. 2001. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27(3):327-31.
19. Clayton-Smith J, Watson P, Ramsden S, Black GC. 2000. Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 356(9232):830-2.
20. Cohen D, Lazar G, Couvert P, Desportes V, Lippe D, Mazet P, and others. 2002. MECP2 mutation in a boy with language disorder and schizophrenia. Am J Psychiatry 159(1):148-9.
21. Cohen DR, Matarazzo V, Palmer AM, Tu Y, Jeon OH, Pevsner J, and others. 2003. Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis. Mol Cell Neurosci 22(4):417-29.
22. Conforti FL, Mazzei R, Magariello A, Patitucci A, Gabriele AL, Muglia M, and others. 2003. Mutation analysis of the MECP2 gene in patients with Rett syndrome. Am J Med Genet 117A(2):184-7.
23. Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, and others. 2001. MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 10(9):941-6.
24. Dotti MT, Orrico A, De Stefano N, Battisti C, Sicurelli F, Severi S, and others. 2002. A Rett syndrome MECP2 mutation that causes mental retardation in men. Neurology 58(2):226-30.
25. Geerdink N, Rotteveel JJ, Lammens M, Sistermans EA, Heikens GT, Gabreels FJ, and others. 2002. MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings. Neuropediatrics 33(1):33-6.
26. Giunti L, Pelagatti S, Lazzerini V, Guarducci S, Lapi E, Coviello S, and others. 2001. Spectrum and distribution of MECP2 mutations in 64 Italian Rett syndrome girls: tentative genotype/phenotype correlation. Brain Dev 23(suppl 1):S242-5.
27. Graziadei GA, Graziadei PP. 1979. Neurogenesis and neuron regeneration in the olfactory system of mammals II. Degeneration and reconstitution of the olfactory sensory neurons after axotomy. J Neurocytol 8:197-213.
28. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. 2001. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27(3):322-6.
29. Hagberg B, Aicardi J, Dias K, Ramos O. 1983. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 14(4): 471-9.
30. Hagberg B, Goutieres F, Hanefeld F, Rett A, Wilson J. 1985. Rett syndrome: criteria for inclusion and exclusion. Brain Dev 7(3):372-3.
31. Hagberg BA, Skjeldal OH. 1994. Rett variants: a suggested model for inclusion criteria. Pediatr Neurol 11(1):5-11.
32. Hendrich B, Bird A. 1998. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18(11):6538-47.
33. Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. 2001. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev 15(6):710-23.
34. Hendrich B, Tweedie S. 2003. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 19(5):269-77.
35. Herbert MR, Ziegler DA, Deutsch CK, O'Brien LM, Lange N, Bakardjiev A, and others. 2003. Dissociations of cerebral cortex, subcortical and cerebral white matter volumes in autistic boys. Brain 126(pt 5):1182-92.
36. Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, and others. 2001. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 56(11):1486-95.
37. Huppke P, Held M, Hanefeld F, Engel W, Laccone F. 2002. Influence of mutation type and location on phenotype in 123 patients with Rett syndrome. Neuropediatrics 33(2):63-8.
38. Huppke P, Laccone F, Kramer N, Engel W, Hanefeld F. 2000. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet 9(9):1369-75.
39. Huttenlocher PR. 1974. Dendritic development in neocortex of children with mental defect and infantile spasms. Neurology 24(3): 203-10.
40. Huttenlocher PR. 1979. Synaptic density in human frontal cortex-developmental changes and effects of aging. Brain Res 163(2):195-205.
41. Huttenlocher PR. 1991. Dendritic and synaptic pathology in mental retardation. Pediatr Neurol 7(2):79-85.
42. Huttenlocher PR. 2000. The neuropathology of phenylketonuria: human and animal studies. Eur J Pediatr 159(suppl 2):S102-6.
43. Huttenlocher PR, de Courten C, Garey LJ, Van der Loos H. 1982. Synaptogenesis in human visual cortex - evidence for synapse elimination during normal development. Neurosci Lett 33(3):247-52.
44. Ichtchenko K, Hata Y, Nguyen T, Ullrich B, Missler M, Moomaw C, and others. 1995. Neuroligin 1: a splice site-specific ligand for beta-neurexins. Cell 81(3):435-43.
45. Imessaoudene B, Bonnefont JP, Royer G, Cormier-Daire V, Lyonnet S, Lyon G, and others. 2001. MECP2 mutation in non-fatal, non-progressive encephalopathy in a male. J Med Genet 38(3):171-4.
46. Irie M, Hata Y, Takeuchi M, Ichtchenko K, Toyoda A, Hirao K, and others. 1997. Binding of neuroligins to PSD-95. Science 277(5331):1511-5.
47. Irwin SA, Galvez R, Greenough WT. 2000. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10(10):1038-44.
48. Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, and others. 2003. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34(1):27-9.
49. Jan MM, Dooley JM, Gordon KE. 1999. Male Rett syndrome variant: application of diagnostic criteria. Pediatr Neurol 20(3):238-40.
50. Jay V, Becker LE, Chan FW, Perry TL Sr. 1991. Puppet-like syndrome of Angelman: a pathologic and neurochemical study. Neurology 41(3):416-22.
51. Jung BP, Jugloff DG, Zhang G, Logan R, Brown S, Eubanks JH. 2003. The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells. J Neurobiol 55(1):86-96.
52. Kemper TL, Bauman M. 1998. Neuropathology of infantile autism. J Neuropathol Exp Neurol 57:645-52.
53. Kemper TL, Bauman ML. 2002. Neuropathology of infantile autism. Mol Psychiatry 7(suppl 2):S12-3.
54. Klauck SM, Lindsay S, Beyer KS, Splitt M, Burn J, Poustka A. 2002. A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome. Am J Hum Genet 70:4.
55. Kleefstra T, Yntema HG, Oudakker AR, Romein T, Sistermans E, Nillessen W, and others. 2002. De novo MECP2 frameshift mutation in a boy with moderate mental retardation, obesity and gynaecomastia. Clin Genet 61(5):359-62.
56. Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Schanen C, and others. 2003. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J Med Genet 40(7):487-93.
57. Kurschner C, Mermelstein PG, Holden WT, Surmeier DJ. 1998. CIPP, a novel multivalent PDZ domain protein, selectively interacts with Kir4.0 family members, NMDA receptor subunits, neurexins, and neuroligins. Mol Cell Neurosci 11(3):161-72.
58. Laccone F, Zoll B, Huppke P, Hanefeld F, Pepinski W, Trappe R. 2002. MECP2 gene nucleotide changes and their pathogenicity in males: proceed with caution. J Med Genet 39(8):586-8.
59. Lee SS, Wan M, Francke U. 2001. Spectrum of MECP2 mutations in Rett syndrome. Brain Dev 23(suppl 1):S138-43.
60. Leonard H, Colvin L, Christodoulou J, Schiavello T, Williamson S, Davis M, and others. 2003. Patients with the R133C mutation: is their phenotype different from patients with Rett syndrome with other mutations? J Med Genet 40(5):e52.
61. Leonard H, Silberstein J, Falk R, Houwink-Manville I, Ellaway C, Raffaele LS, and others. 2001. Occurrence of Rett syndrome in boys. J Child Neurol 16(5):333-8.
62. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, and others. 1992. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69(6):905-14.
63. Lobo-Menendez F, Sossey-Alaoui K, Bell JM, Copeland-Yates SA, Plank SM, Sanford SO, and others. 2003. Absence of MeCP2 mutations in patients from the South Carolina autism project. Am J Med Genet 117B(1):97-101.
64. Maiwald R, Bonte A, Jung H, Bitter P, Storm Z, Laccone F, and others. 2002. De novo MECP2 mutation in a 46,XX male patient with Rett syndrome. Neurogenetics 4(2):107-8.
65. Meloni I, Bruttini M, Longo I, Mari F, Rizzolio F, D'Adamo P, and others. 2000. A mutation in the Rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet 67(4):982-5.
66. Millar CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, Hendrich B, and others. 2002. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297(5580):403-5.
67. Monros E, Armstrong J, Aibar E, Poo P, Canos I, Pineda M. 2001. Rett syndrome in Spain: mutation analysis and clinical correlations. Brain Dev 23(suppl 1):S251-3.
68. Nan X, Campoy FJ, Bird A. 1997. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88(4):471-81.
69. Nan X, Meehan RR, Bird A. 1993. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 21(21):4886-92.
70. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, and others. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683):386-9.
71. Nan X, Tate P, Li E, Bird A. 1996. DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol 16(1):414-21.
72. Nguyen T, Sudhof TC. 1997. Binding properties of neuroligin 1 and neurexin 1beta reveal function as heterophilic cell adhesion molecules. Biol Chem 272(41):26032-9.
73. Nielsen JB, Henriksen KF, Hansen C, Silahtaroglu A, Schwartz M, Tommerup N. 2001. MECP2 mutations in Danish patients with Rett syndrome: high frequency of mutations but no consistent correlations with clinical severity or with the X chromosome inactivation pattern. Eur J Hum Genet 9(3):178-84.
74. Obata K, Matsuishi T, Yamashita Y, Fukuda T, Kuwajima K, Horiuchi I, and others. 2000. Mutation analysis of the methyl-CpG binding protein 2 gene (MECP2) in patients with Rett syndrome. J Med Genet 37(8):608-10.
75. Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, and others. 2000. MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett 481(3):285-8.
76. Percy AK. 2002. Rett syndrome. Current status and new vistas. Neurol Clin 20(4):1125-41.
77. Ravn K, Nielsen JB, Uldall P, Hansen FJ, Schwartz M. 2003. No correlation between phenotype and genotype in boys with a truncating MECP2 mutation. J Med Genet 40(1):e5.
78. Raymond GV, Bauman ML, Kemper TK. 1996. Hippocampus in autism: a Golgi analysis. Acta Neuropathology 91:117-9.
79. Rett A. 1966. [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wien Med Wochenschr 116(37):723-6.
80. Ronnett GV, Leopold D, Cai X, Hoffbuhr KC, Moses L, Hoffman EP, and others. 2003. Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol 54(2):206-18.
81. Scheiffele P, Fan J, Choih J, Fetter R, Serafini T. 2000. Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons. Cell 101(6):657-69.
82. Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. 2001. Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. Neuropediatrics 32(3): 162-4.
83. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, and others. 2002. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35(2):243-54.
84. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. 2002. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 11(2):115-24.
85. Shahbazian MD, Zoghbi HY. 2001. Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr Opin Neurol 14(2):171-6.
86. Shahbazian MD, Zoghbi HY. 2002. Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am J Hum Genet 71(6):1259-72.
87. Song JY, Ichtchenko K, Sudhof TC, Brose N. 1999. Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. Proc Natl Acad Sci U S A 96(3):1100-5.
88. Stancheva I, Collins AL, Van den Veyver IB, Zoghbi HY, Meehan R. 2003. A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by Notch in Xenopus embryos. Mol Cell 12:425-35.
89. Topcu M, Akyerli C, Sayi A, Toruner GA, Kocoglu SR, Cimbis M, and others. 2002. Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. Eur J Hum Genet 10(1):77-81.
90. Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, Fontes M. 2000. Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 55(8):1188-93.
91. Vourc'h P, Bienvenu T, Beldjord C, Chelly J, Barthelemy C, Muh JP, and others. 2001. No mutations in the coding region of the Rett syndrome gene MECP2 in 59 autistic patients. Eur J Hum Genet 9(7):556-8.
92. Wade PA. 2001. Methyl CpG-binding proteins and transcriptional repression. Bioessays 23(12):1131-7.
93. Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, and others. 1999. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet 65(6):1520-9.
94. Weaving LS, Williamson SL, Bennetts B, Davis M, Ellaway CJ, Leonard H, and others. 2003. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am J Med Genet 118A(2):103-14.
95. Winnepenninckx B, Errijgers V, Hayez-Delatte F, Reyniers E, Frank Kooy R. 2002. Identification of a family with nonspecific mental retardation (MRX79) with the A140V mutation in the MECP2 gene: is there a need for routine screening? Hum Mutat 20(4):249-52.
96. Yamada Y, Miura K, Kumagai T, Hayakawa C, Miyazaki S, Matsumoto A, and others. 2001. Molecular analysis of Japanese patients with Rett syndrome: identification of five novel mutations and genotype-phenotype correlation. Hum Mutat 18(3):253.
97. Yamashita Y, Kondo I, Fukuda T, Morishima R, Kusaga A, Iwanaga R, and others. 2001. Mutation analysis of the methyl-CpG-binding protein 2 gene (MECP2) in Rett patients with preserved speech. Brain Dev 23(suppl 1):S157-60.
98. Yntema HG, Kleefstra T, Oudakker AR, Romein T, De Vries BB, Nillesen W, and others. 2002. Low frequency of MECP2 mutations in mentally retarded males. Eur J Hum Genet 10(8):487-90.
99. Yntema HG, Oudakker AR, Kleefstra T, Hamel BC, van Bokhoven H, Chelly J, and others. 2002. In-frame deletion in MECP2 causes mild nonspecific mental retardation. Am J Med Genet 107(1):81-3.
100. Zappella M, Gillberg C, Ehlers S. 1998. The preserved speech variant: a subgroup of the Rett complex: a clinical report of 30 cases. J Autism Dev Disord 28(6):519-26.
101. Zappella M, Meloni I, Longo I, Canitano R, Hayek G, Rosaia L, and others. 2003. Study of MECP2 gene in Rett syndrome variants and autistic girls. Am J Med Genet 119B(1):102-7.
102. Zappella M, Meloni I, Longo I, Hayek G, Renieri A. 2001. Preserved speech variants of the Rett syndrome: molecular and clinical analysis. Am J Med Genet 104(1):14-22.
103. Zeev BB, Yaron Y, Schanen NC, Wolf H, Brandt N, Ginot N, and others. 2002. Rett syndrome: clinical manifestations in males with MECP2 mutations. J Child Neurol 17(1):20-4.
104. Zhao X, Ueba T, Christie BR, Barkho B, McConnell MJ, Nakashima K, and others. 2003. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc Natl Acad Sci U S A 100(11):6777-82.